[HTML][HTML] The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind …
…, C Jordán-Iborra, J Brew, F Carmona-Torre… - …, 2021 - thelancet.com
Background Ivermectin inhibits the replication of SARS-CoV-2 in vitro at concentrations not
readily achievable with currently approved doses. There is limited evidence to support its …
readily achievable with currently approved doses. There is limited evidence to support its …
Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies
…, M Tortajada, F Carmona-Torre… - Translational …, 2021 - Elsevier
COVID-19 patients elicit strong responses to the nucleocapsid (N) protein of SARS-CoV-2
but binding antibodies are also detected in prepandemic individuals, indicating potential …
but binding antibodies are also detected in prepandemic individuals, indicating potential …
Highly sensitive and specific multiplex antibody assays to quantify immunoglobulins M, A, and G against SARS-CoV-2 antigens
…, P Martínez de Aguirre, F Carmona-Torre… - Journal of clinical …, 2021 - Am Soc Microbiol
Reliable serological tests are required to determine the prevalence of antibodies against
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to characterize immunity …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to characterize immunity …
[HTML][HTML] Dysautonomia in COVID-19 patients: a narrative review on clinical course, diagnostic and therapeutic strategies
F Carmona-Torre, A Mínguez-Olaondo… - Frontiers in …, 2022 - frontiersin.org
Introduction On March 11, 2020, the World Health Organization sounded the COVID-19
pandemic alarm. While efforts in the first few months focused on reducing the mortality of infected …
pandemic alarm. While efforts in the first few months focused on reducing the mortality of infected …
[HTML][HTML] Therapeutic versus prophylactic bemiparin in hospitalized patients with nonsevere COVID-19 pneumonia (BEMICOP study): an open-label, multicenter …
M Marcos-Jubilar, F Carmona-Torre… - Thrombosis and …, 2022 - thieme-connect.com
Thromboprophylaxis with low molecular weight heparin in hospitalized patients with COVID-19
is mandatory, unless contraindicated. Given the links between inflammation and …
is mandatory, unless contraindicated. Given the links between inflammation and …
[HTML][HTML] Neutrophil extracellular traps, local IL-8 expression, and cytotoxic T-lymphocyte response in the lungs of patients with fatal COVID-19
…, M Rodríguez-Mateos, G Reina, F Carmona-Torre… - Chest, 2022 - Elsevier
Background Excessive inflammation is pathogenic in the pneumonitis associated with
severe COVID-19. Neutrophils are among the most abundantly present leukocytes in the …
severe COVID-19. Neutrophils are among the most abundantly present leukocytes in the …
[HTML][HTML] Humoral and cellular immune response over 9 months of mRNA-1273, BNT162b2 and ChAdOx1 vaccination in a University Hospital in Spain
…, A Fernández-Montero, F Carmona-Torre… - Scientific Reports, 2022 - nature.com
Scarce data have been reported about cellular immunity and longevity for different COVID-19
vaccination schedules. We carried out a prospective study enrolling 709 healthcare …
vaccination schedules. We carried out a prospective study enrolling 709 healthcare …
[HTML][HTML] The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe …
…, G Moncunill, A Casellas, F Carmona-Torre… - Trials, 2020 - Springer
Objectives The primary objective is to determine the efficacy of a single dose of ivermectin,
administered to low risk, non-severe COVID-19 patients in the first 48 hours after symptom …
administered to low risk, non-severe COVID-19 patients in the first 48 hours after symptom …
Real-life use of ceftolozane/tazobactam for the treatment of bloodstream infection due to Pseudomonas aeruginosa in neutropenic hematologic patients: a matched …
…, J Aguilar-Company, F Carmona-Torre… - Microbiology …, 2022 - Am Soc Microbiol
We sought to assess the characteristics and outcomes of neutropenic hematologic patients
with Pseudomonas aeruginosa (PA) bloodstream infection (BSI) treated with ceftolozane-…
with Pseudomonas aeruginosa (PA) bloodstream infection (BSI) treated with ceftolozane-…
Histopathological findings in fatal COVID-19 severe acute respiratory syndrome: preliminary experience from a series of 10 Spanish patients
B Recalde-Zamacona, L García-Tobar, A Argueta… - Thorax, 2020 - thorax.bmj.com
In December 2019, an outbreak of severe acute respiratory syndrome associated to SARS-CoV2
was reported in Wuhan, China. To date, little is known on histopathological findings in …
was reported in Wuhan, China. To date, little is known on histopathological findings in …